Pharmaceutical Information |
Drug Name |
Epirubicin hydrochloride |
Drug ID |
BADD_D00785 |
Description |
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. |
Indications and Usage |
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. |
Marketing Status |
approved |
ATC Code |
L01DB03 |
DrugBank ID |
DB00445
|
KEGG ID |
D02214
|
MeSH ID |
D015251
|
PubChem ID |
65348
|
TTD Drug ID |
D0C9XJ
|
NDC Product Code |
0143-9202; 0009-5091; 0009-5093; 77391-002; 0143-9203 |
UNII |
22966TX7J5
|
Synonyms |
Epirubicin | 4'-Epidoxorubicin | 4' Epidoxorubicin | 4'-Epi-Doxorubicin | 4' Epi Doxorubicin | 4'-Epi-Adriamycin | 4' Epi Adriamycin | 4'-Epiadriamycin | 4' Epiadriamycin | 4'-Epi-DXR | 4' Epi DXR | EPI-cell | EPI cell | EPIcell | Epilem | Farmorubicina | IMI-28 | IMI 28 | IMI28 | NSC-256942 | NSC 256942 | NSC256942 | Ellence | Pharmorubicin | Farmorubicine | Farmorubicin | Epirubicin Hydrochloride | Hydrochloride, Epirubicin |
|
Chemical Information |
Molecular Formula |
C27H29NO11.ClH |
CAS Registry Number |
25316-40-9 |
SMILES |
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
.Cl |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|